Clofarabine is a chemotherapeutic agent that has been approved for use in the treatment of acute lymphoblastic leukemia (ALL) in pediatric patients. It is also being investigated for use in other hematological malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Clofarabine has the chemical name (E)-2-Cyano-2-(5-(2-chloroethyl)-4-methyl-1H-pyrrole-3-carbonylamino)vinyl-1-beta-D-arabinofuranosyladenine, a molecular formula of C10H11ClN5O3, formula weight of 303.68 g/mol and CAS No. 123318-82-1.
Top 10 Keywords related to Clofarabine from Google are:
Synonyms of Clofarabine are Clofarex, Clolar, 2-chloro-9-(5-(deoxy-arabinofuranosyl)-imidazo[4,5-b]pyridin-1-yl)-8-(1-cyano-2-hydroxyvinyl)-adenine.
Health Benefits of Clofarabine: Clofarabine can be used effectively for the treatment of acute lymphoblastic leukemia (ALL), a rapidly progressive hematologic malignancy. It is indicated for the treatment of children and adolescents from 1 to 21 years of age with relapsed or refractory ALL. Clofarabine has also been investigated for use in adults with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Potential Effects of Clofarabine: Clofarabine is a nucleoside analog that interferes with DNA synthesis, leading to the inhibition of cell growth and division. It also induces apoptosis, or programmed cell death, in cancer cells. Clofarabine has been found to be effective as a single agent in the treatment of relapsed or refractory ALL in children and adolescents, with response rates ranging from 30% to 44%. It has also been used in combination with other chemotherapeutic agents.
Product Mechanism of action: Clofarabine is a purine nucleoside analog that is phosphorylated within cells to the active triphosphate form. It inhibits DNA synthesis by incorporation into DNA and RNA chains, leading to chain termination and inhibition of cell growth and division. Clofarabine also induces apoptosis or programmed cell death in cancer cells by activating the caspase cascade.
Safety: Clofarabine is generally safe and well-tolerated in children and adolescents with ALL. The most common adverse reactions reported with the use of clofarabine include fever, nausea, vomiting, diarrhea, cough, headache, and rash. More serious adverse reactions include myelosuppression, infections, and hepatic veno-occlusive disease.
Side Effects: The side effects of clofarabine depend on the dose and duration of treatment. Common side effects include nausea, vomiting, fever, diarrhea, and rash. Serious adverse reactions include myelosuppression, infections, and hepatic veno-occlusive disease. Patients receiving clofarabine should be closely monitored for signs of infection, bleeding, or hepatic dysfunction.
Dosing Information: The recommended dose of clofarabine for the treatment of relapsed or refractory ALL in children and adolescents is 52 mg/m2/day for five consecutive days. The dose may be repeated every two to six weeks depending on the response and toxicity. The dose and duration of treatment may vary depending on the patient's age, weight, and overall health.
Conclusion: Clofarabine is a chemotherapeutic agent that has been approved for use in the treatment of acute lymphoblastic leukemia (ALL) in pediatric patients. It is also being investigated for use in other hematological malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Clofarabine interferes with DNA synthesis, leading to the inhibition of cell growth and division, and induces apoptosis or programmed cell death in cancer cells. It is generally safe and well-tolerated in children and adolescents with ALL, but serious adverse reactions may occur. Patients receiving clofarabine should be closely monitored for signs of infection, bleeding, or hepatic dysfunction. The recommended dose and duration of treatment may vary depending on the patient's age, weight, and overall health
